Gary A. Enos, Editor
A Toronto-based company is looking to have an impact on the treatment of opioid addiction by exploring the potential of psychedelics, an area of study that to this point has seen more intense activity in the mental health field.
Mind Medicine Inc. (Mindmed) announced this week that it has acquired the drug development program for 18-MC (18-methoxycoronaridine), a synthetic derivative of the psychedelic drug ibogaine. The company is preparing 18-MC ...
There is no medically approved single-dose cure for opioid addiction in the United States or anywhere alse in the world for that matter.
Those that want to quit opioids on sheer willpower alone are fighting a losing battle and are in for the hell of an experience — literally. Immediately withdrawing from an opioid or going cold turkey can make a user wish he were dead.
Once an opioid is removed, “the body responds ...
TORONTO, Sept. 16, 2019 /PRNewswire/ — Mind Medicine, Inc. (“Mindmed”), the leading neuro-pharmaceutical company focused on discovering and developing medicines based on psychedelics, has finalized the acquisition of the 18-MC drug development program, an anti-addictive molecule that was previously funded by the National Institute on Drug Abuse (“NIDA”). Mindmed acquired the project from Savant HWP Inc., whose leadership team of top researchers and drug developers will also join ...
At first, Lotsof had no desire to spend a day and a half hallucinating, so he gave the dose to a friend. A month later, his friend called in the middle of the night and told him the drug was so revolutionary that they had to “tell Congress.” Lotsof decided he had to try it himself. His first experience with the drug was unlike anything else. There were endless hours of weird visions—a ...
Central to this tradition is the use of a psychoactive plant root called iboga which is used in ritualistic ceremonies. Extracts from the plant have also …